Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis
Maria Comas, Ilia Toshkov, Karen K. Kuropatwinski, et al.
Aging (2012) Vol. 4, Iss. 10, pp. 715-722
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

Aging and age‐related diseases: from mechanisms to therapeutic strategies
Zhe Li, Zhenkun Zhang, Yikun Ren, et al.
Biogerontology (2021) Vol. 22, Iss. 2, pp. 165-187
Open Access | Times Cited: 420
Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island
Sebastian I. Arriola Apelo, Dudley W. Lamming
The Journals of Gerontology Series A (2016) Vol. 71, Iss. 7, pp. 841-849
Open Access | Times Cited: 207
Effect of rapamycin on aging and age-related diseases—past and future
Ramasamy Selvarani, Sabira Mohammed, Arlan Richardson
GeroScience (2020) Vol. 43, Iss. 3, pp. 1135-1158
Open Access | Times Cited: 201
BMAL1-dependent regulation of the mTOR signaling pathway delays aging
Rohini V. Khapre, Anna A. Kondratova, Sonal A. Patel, et al.
Aging (2014) Vol. 6, Iss. 1, pp. 48-57
Open Access | Times Cited: 199
Targeting the biology of aging with mTOR inhibitors
Joan B. Mannick, Dudley W. Lamming
Nature Aging (2023) Vol. 3, Iss. 6, pp. 642-660
Open Access | Times Cited: 175
Cancer prevention with rapamycin
Mikhail V. Blagosklonny
Oncotarget (2023) Vol. 14, Iss. 1, pp. 342-350
Open Access | Times Cited: 46
mTOR pathway in colorectal cancer: an update
Maria Giovanna Francipane, Eric Lagasse
Oncotarget (2013) Vol. 5, Iss. 1, pp. 49-66
Open Access | Times Cited: 171
Longevity, aging and rapamycin
Dan Ehninger, Frauke Neff, Kan Xie
Cellular and Molecular Life Sciences (2014) Vol. 71, Iss. 22, pp. 4325-4346
Open Access | Times Cited: 160
Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil
Javier A. Menéndez, Jorge Joven, Gerard Aragonès, et al.
Cell Cycle (2013) Vol. 12, Iss. 4, pp. 555-578
Open Access | Times Cited: 139
Geroconversion: irreversible step to cellular senescence
Mikhail V. Blagosklonny
Cell Cycle (2014) Vol. 13, Iss. 23, pp. 3628-3635
Open Access | Times Cited: 135
Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Gabriella Testa, Fiorella Biasi, Giuseppe Poli, et al.
Current Pharmaceutical Design (2014) Vol. 20, Iss. 18, pp. 2950-2977
Closed Access | Times Cited: 135
Aging is not programmed
Mikhail V. Blagosklonny
Cell Cycle (2013) Vol. 12, Iss. 24, pp. 3736-3742
Open Access | Times Cited: 129
TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists
Mikhail V. Blagosklonny
Cell Death and Disease (2013) Vol. 4, Iss. 12, pp. e964-e964
Open Access | Times Cited: 115
How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story
Arlan Richardson, Verónica Galván, Ai-Ling Lin, et al.
Experimental Gerontology (2014) Vol. 68, pp. 51-58
Open Access | Times Cited: 113
CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: Duration of cell cycle arrest and MTOR activity determine geroconversion
Olga V. Leontieva, Mikhail V. Blagosklonny
Cell Cycle (2013) Vol. 12, Iss. 18, pp. 3063-3069
Open Access | Times Cited: 108
Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
Alex Zhavoronkov
Aging (2020) Vol. 12, Iss. 8, pp. 6492-6510
Open Access | Times Cited: 90
Mitophagy Receptors and Mediators: Therapeutic Targets in the Management of Cardiovascular Ageing
Amir Ajoolabady, Hamid Aslkhodapasandhokmabad, Ayuob Aghanejad, et al.
Ageing Research Reviews (2020) Vol. 62, pp. 101129-101129
Closed Access | Times Cited: 81
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1
Maria Giovanna Francipane, Eric Lagasse
Oncotarget (2013) Vol. 4, Iss. 11, pp. 1948-1962
Open Access | Times Cited: 93
mTORC1 and p53
Paul Hasty, Z. Dave Sharp, Tyler J. Curiel, et al.
Cell Cycle (2012) Vol. 12, Iss. 1, pp. 20-25
Open Access | Times Cited: 92
Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors
Carolina B. Livi, Rulon L. Hardman, Barbara A. Christy, et al.
Aging (2013) Vol. 5, Iss. 2, pp. 100-110
Open Access | Times Cited: 84
p53, a translational regulator: contribution to its tumour-suppressor activity
Virginie Marcel, Frédéric Catez, Jean‐Jacques Diaz
Oncogene (2015) Vol. 34, Iss. 44, pp. 5513-5523
Open Access | Times Cited: 83
From rapalogs to anti-aging formula
Mikhail V. Blagosklonny
Oncotarget (2017) Vol. 8, Iss. 22, pp. 35492-35507
Open Access | Times Cited: 82
Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin
Irina G. Popovich, Vladimir N. Anisimov, Mark A. Zabezhinski, et al.
Cancer Biology & Therapy (2014) Vol. 15, Iss. 5, pp. 586-592
Open Access | Times Cited: 79
Rapamycin, Autophagy, and Alzheimer's Disease.
Zhiyou Cai, Liang‐Jun Yan
PubMed (2013)
Closed Access | Times Cited: 76
Physiological frailty index (PFI): quantitative in-life estimate of individual biological age in mice
Marina P. Antoch, Michelle Wrobel, Karen K. Kuropatwinski, et al.
Aging (2017) Vol. 9, Iss. 3, pp. 615-626
Open Access | Times Cited: 63
Page 1 - Next Page

Scroll to top